Identification of a novel conformationally constrained glucagon receptor antagonist

Identification of orally active, small molecule antagonists of the Glucagon Receptor represents a novel treatment paradigm for the management of type 2 diabetes mellitus. The present work discloses novel Glucagon Receptor antagonists, identified via conformational constraint of current existing literature antagonists. Optimization of lipophilic ligand efficiency (LLE or LipE) culminated in enantiomers (+)-trans-26 and (-)-trans-27 which exhibit good physicochemical and in vitro drug metabolism profiles. In vivo, significant pharmacokinetic differences were noted with the two enantiomers, which were primarily driven through differences in clearance rates. Enantioselective oxidation by Cytochrome P450 was ruled out as a causative factor for pharmacokinetic differences.